Table 1.
Clinical trials testing the efficacy of camostat mesilate for the treatment of COVID-19
| NCT number (clinicaltrials.gov) |
Title | Status | Interventions | Phase | Location |
|---|---|---|---|---|---|
| NCT04353284 | Camostat Mesylate in COVID-19 Outpatients | Recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 2 | United States |
| NCT04583592 | Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) | Active, not recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 2 | United States |
| NCT04524663 | Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients | Recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 2 | United States |
| NCT04608266 | CAMOVID: Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection – COVID-19 in Ambulatory Adult Patients | Recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 3 | France |
| NCT04625114 | The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden | Recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 2 | Belgium |
| NCT04455815 | A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home | Recruiting | Drug: Camostat mesilate | Phase 2 Phase 3 | UK |
| NCT04662073 | COVID-19 Outpatient Pragmatic Platform Study (COPPS) – Camostat Sub-Protocol | Not yet recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 2 | United States |
| NCT04652765 | Camostat With Bicalutamide for COVID-19 | Recruiting | Drug: Camostat Mesilate Drug: Bicalutamide | Phase 1 | United States |
| NCT04730206 | The DAWN Camostat Trial for Ambulatory COVID-19 Patients | Not yet recruiting | Drug: Camostat mesilate Placebo controlled |
Phase 3 | Belgium |
| NCT04750759 | Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat | Recruiting | Drug: Niclosamide + Camostat mesilate Placebo controlled |
Phase 2 | Germany |
| NCT04657497 | A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) | Recruiting | Drug: FOY-305 Placebo controlled |
Phase 3 | Japan |
| NCT04355052 | Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ‘no Treatment’ in SARS CoV 2 Virus | Recruiting | Drug: hydroxychloroquine with camostat mesilate Drug: Hydroxychloroquine with Azithromycin Placebo controlled |
Phase 3 | Israel |
| NCT04530617 | Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients | Recruiting | Drug: Camostat Mesilate Drug: Artemisia Annua Leaf Placebo controlled |
Phase 2 | Mexico |
| NCT04681430 | Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals | Recruiting | Biological: Convalescent plasma Drug: Camostat Mesilate Placebo controlled |
Phase 2 | Germany |
| NCT04662086 | COVID-19 Outpatient Pragmatic Platform Study (COPPS) – Master Protocol | Not yet recruiting | Drug: Acebilustat Drug: Camostat Mesilate Placebo controlled |
Phase 2 | United States |
| NCT04321096 | The Impact of Camostat Mesilate on COVID-19 Infection | Active, not recruiting | Drug: Camostat Mesilate Placebo controlled |
Phase 1 Phase 2 | Denmark |
| NCT04374019 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | Recruiting | Drug: Ivermectin Drug: Camostat Mesilate Drug: Artesunate |
Phase 2 | United States |
| NCT04470544 | Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 | Recruiting | Drug: Camostat Mesilate Placebo controlled |
Phase 2 | United States |
| NCT04644705 | Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat | Recruiting | Drug: Niclosamide with Camostat Mesilate Drug: Placebo controlled |
Phase 1 | Germany |
| NCT04721535 | A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2 | Not yet recruiting | Drug: DWJ1248 Placebo controlled |
Phase 3 | South Korea |
| NCT04521296 | Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo | Not yet recruiting | Drug: DWJ1248 Placebo controlled |
Phase 2 | South Korea |
| NCT04713176 | Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients | Recruiting | Drug: DWJ1248 with Remdesivir Placebo controlled |
Phase 3 | South Korea |